Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8738775rdf:typepubmed:Citationlld:pubmed
pubmed-article:8738775lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C0023911lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C1705165lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C0444506lld:lifeskim
pubmed-article:8738775lifeskim:mentionsumls-concept:C2700061lld:lifeskim
pubmed-article:8738775pubmed:issue3lld:pubmed
pubmed-article:8738775pubmed:dateCreated1996-10-25lld:pubmed
pubmed-article:8738775pubmed:abstractTextCyclosporin A (CsA) absorption is low and variable after liver transplantation, and during the intravenous-oral transition period CsA concentrations may not be maintained within the therapeutic range. Trough whole blood CsA concentrations were measured by high-performance liquid chromatography before and after the transition period in 27 liver transplant patients. Mean (SD) CsA concentrations decreased from 291 (92) to 198 (96) ng/ml (p < 0.001). When analyzed on individual charts, a decrease was observed in 15 of 27 patients and it was associated with a duration of 2 days or less (p < 0.01) and a total bilirubin value below 3.5 mg/dl (p < 0.05). Our results show that, despite therapeutic drug monitoring, CsA blood concentrations may decrease during the intravenous-oral transition period.lld:pubmed
pubmed-article:8738775pubmed:languageenglld:pubmed
pubmed-article:8738775pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8738775pubmed:citationSubsetIMlld:pubmed
pubmed-article:8738775pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8738775pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8738775pubmed:statusMEDLINElld:pubmed
pubmed-article:8738775pubmed:monthJunlld:pubmed
pubmed-article:8738775pubmed:issn0163-4356lld:pubmed
pubmed-article:8738775pubmed:authorpubmed-author:MiguetJ PJPlld:pubmed
pubmed-article:8738775pubmed:authorpubmed-author:MantionGGlld:pubmed
pubmed-article:8738775pubmed:authorpubmed-author:Bresson-Hadni...lld:pubmed
pubmed-article:8738775pubmed:authorpubmed-author:PaintaudGGlld:pubmed
pubmed-article:8738775pubmed:authorpubmed-author:BechtelP RPRlld:pubmed
pubmed-article:8738775pubmed:authorpubmed-author:MaboundouC...lld:pubmed
pubmed-article:8738775pubmed:issnTypePrintlld:pubmed
pubmed-article:8738775pubmed:volume18lld:pubmed
pubmed-article:8738775pubmed:ownerNLMlld:pubmed
pubmed-article:8738775pubmed:authorsCompleteYlld:pubmed
pubmed-article:8738775pubmed:pagination310-4lld:pubmed
pubmed-article:8738775pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:meshHeadingpubmed-meshheading:8738775-...lld:pubmed
pubmed-article:8738775pubmed:year1996lld:pubmed
pubmed-article:8738775pubmed:articleTitleEffect of the transition from intravenous to oral dosing on cyclosporin-A trough concentrations in liver transplant patients.lld:pubmed
pubmed-article:8738775pubmed:affiliationDepartment of Clinical Pharmacology, Besançon University Hospital, France.lld:pubmed
pubmed-article:8738775pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8738775pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8738775pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8738775pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed